DOCSLIB.ORG

Expression Solutions

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Expression Solutions expression solutions VectorGPS(R) Expression vectors Electra cloning system GeneGPS optimization Gene synthesis & custom cloning expression Expression of active protein at high levels requires selecting the best coding sequence for a gene and the best vector from which to express it. ATUM’s empirically-derived codon optimization ensures that your gene is designed for efficient translation in your chosen host. Our expression vectors combine control elements that work well together for mammalian, bacterial or yeast systems. For especially challenging proteins or new host systems, we can develop customized solutions. We can even test the expression or produce the protein for you. ATUM has developed a variety of expression vectors, using Design-of- Experiment techniques to test interactions between control elements, secretion signals and functional tags. Vector elements also interact with the gene being expressed, so there is no one vector that will work for all proteins. We have selected the vectors in our catalog to maximize the chances that at least one will have the expression properties you need. contents Mammalian Expression: Vectors and Services 2-11 Transient, stable, Leap-In transposase and lentivirus vectors for high protein expression. Bacterial Expression Vectors 12-13 High protein expression, with a choice of promoters, markers, tags, secretion signals and more. Yeast Expression Vectors 14-15 High protein expression, with a choice of promoters, markers, tags, secretion signals and more. Electra Vector System(R) 16 One tube, 5 minutes, any ORF. Scarless cloning in bacterial, mammalian and yeast systems. GeneGPS(R) Optimization 17 One tube, 5 minutes, any ORF. Scarless cloning in bacterial, mammalian and yeast systems. Expression Services 18 Gene synthesis, Custom Cloning, LSPs, and Expression Test. VectorGPS(R) 19 Discover the vector that works best for your research. mammalian expression: vectors & services ATUM offers vectors for transient and stable 70 mammalian protein expression. Vectors shown here are available from the ATUM catalog as easy 60 to clone Electra kits. Any synthetic gene made by pD2610-v1 ATUM can also be cloned into these vectors. 50 pD2610-v12 pD2610-v26 40 pD2600 Transient Expression Vectors pD2610-v10 pD2610-v14 We offer around 30 different transient vector 30 configurations, which we identified by testing over pD2610-v13 pD2610-v9 pD2610-v3 250 different combinations of promoters, introns, 20 pD2610-v4 pD2610-v23 pcDNA3.4 pTT5 pD2610-v27 polyadenylation sequences and viral amplifiers in pD2610-v2 pD2610-v5 pD2610-v28 HEK and CHO cell lines. pD2610-v6 10 pD2610-v11 pD2610-v29 pD609 pD2610-v17 HEK293 Expression (Fluorescence X1000) pD2610-v19 pD2610-v16 Intron ORF pD2610-v8 pD2610-v20pD2610-v18 0 pD2610-v7 pD2610-v15 0 10 20 30 40 50 CHO-K1 Expression (Fluorescence X1000) polyA Globin BGH... Promoter CMV 120 EF1a GAPDH... pD2610-v5 Enhancer pD2600 100 CMV EF1a pD2610-v2 SV40 Synthetic... pD2610-v1 80 pcDNA3.4 pD2610-v14 pD2610-v13 SV40 ori EBV oriP pD2610-v12 pD2610-v23 SV40 large T-Ag pTT5 pD2610-v2p6D2610-v4 pD2610-v10 Bacterial resistance marker EBNA... 60 pD2610-v9 Ori pD2610-v3 pD2610-v29 The reason we have so many vectors is that even 40 pD2610-v27 similar cell lines seem to have different control pD2610-v11 Expression (Fluorescence X1000) pD2610-v30 element preferences, as is shown in the graphs TM 20 pD2610-v17 below. Added to this, differences in desired pD2610-v15 pD2610-v6 duration of culture and the localization of the Expi293 0 pD2610-v28 protein being produced (intracellular, membrane- 0 10 20 30 40 50 60 70 bound or secreted) make it impossible for a single Expi-CHOTM Expression (Fluorescence X1000) vector to meet all needs. DasherGFP expression compared in transiently transfected CHO and HEK293 cells. Cells were harvested from independent triplicate transfections and DasherGFP fluorescence was measured 72 hours post-transfection. 2 www.atum.bio for your protein, please call us! Or let us make the protein for you. for the protein us make let callus!Or please protein, your for need helpinchoosingavector you soif andCHO, inHEK week every proteins of hundreds express We anIRES. through coupling expression chainsby and light heavy antibody’s of co-expression enable construct) (single CHO cells. configurations vector dualexpression ATUM and HEK293 transfected transiently in production Antibody Vectors Expression pD2600 Transient HEK Expression - Antibody conc. in µg/ml 30 40 50 20 35 45 25 -5 10 15 50 0 0 0 0 0 0 0 0 0 0 0 pD2610-v1 pD2610-v2 pD2610-v3 pD2610-v4 pD2610-v5 pD2610-v6 pD2610-v7 pD2610-v8 pD2610-v9 chain quantitation by ELISA, 6 days post-transfection. post-transfection. 6days ELISA, by chain quantitation heavy by measured was expression Antibody cells. CHO and inHEK293 triplicate carriedout in were transfections Fugene; using confluency at70-80% transfected Cells were pD2610-v10 pD2610-v11 MM Ve Ri tu pD2610-v12 ct 12 xa ib 1V ix n pD2610-v13d pD2610-v13 He He 23 pD2610-v14 LN rc rc ep ep pD2610-v15 ti ti MAMMALIAN EXPRESSION n n pD2610-v16 (A TU pD2610-v17 M co pD2610-v18 do n 3 op pD2610-v19 ti mi pD2610-v20 ze d) transient expression services Protein Expression Whether you need milligrams of thousands of Our versatile platform produces proteins including proteins as part of a drug candidate screening antibodies, Fabs and Fc fusions at 1ml - 20l scales. process, or grams of a few proteins for in depth Delivery times are accelerated because sequence characterization of your best leads, we can help. and vector optimization, synthesis & cloning, expression and purification are all under one roof. An automated, bar-coded, time-stamped process can screen thousands of expressed proteins in parallel. For large screening projects, it can be worth spending time optimizing the components. This can include: ⬤ Optimizing codon bias and eliminating potentially problematic cryptic splice sites from DNA sequences. ⬤ Selecting efficient signal sequences for secreted proteins. ⬤ Identifying the best vector. ⬤ Balancing chain ratios for antibodies or other proteins with multiple polypeptides. 4 www.atum.bio MAMMALIAN EXPRESSION The graph shows expression 250 of twelve representative murine antibody sequences 200 for a screening project. The genes were cloned into 5 different vectors, transfected 150 into HEK cells and harvested 5 days later. Based on this Titer in mg/l 100 data we selected vector #2 for further process 50 development. 0 1 2 3 4 5 Vectors After optimizing secretion 250 signals and constant region coding region as well as the l vector sequence, we were 200 able to exceed the target productivity of 75 mg/l 150 in >95% of the expressed antibodies. 100 Antibody Yield in mg/ 50 0 1 1 1 7 5 9 3 3 9 61 13 97 37 73 25 49 12 85 18 15 14 16 19 13 10 Constructs Proteins are delivered with a rigorous QC package. ⬤ Protein concentration (A280) ⬤ Molecular weight (reducing and non-reducing gel electrophoresis) ⬤ Aggregation (size exclusion chromatography) And optionally: ⬤ Endotoxin (Charles River test) ⬤ Glycan analysis (mass spectroscopy) ⬤ Binding affinity (Surface plasmon resonance with the Octet) 5 pD2500 & pD3600 stable vectors ATUM offers two stable vector series: the pD2500s and pD3600s, which share a similar structure. The pD2500s are compatible with one of our Leap-In transposases (LPN-1), but they do not require Marker promoter Mammalian marker Promoter 1 a transposase for good levels of expression. ORF1 signal The pD3600s are compatible with both Marker polyA of our Leap-In transposases (LPN-1 ORF1 and LPN-2), and we recommend that ORF1 poly A they only be used with a transposase. Insulator intervening sequence This is because we have deliberately attenuated the selectable markers in Leap-In Transposon the pD3600s, so multiple integration P kanamycin events are required for cell viability Promoter 2 under selection. The pD3600s are M_Kanamycin-r_* therefore capable of higher expression yields. ORF2 signal Bacterial Origin ORF2 The pD2500 and pD3600 vectors are Transposon right border ORF2 polyA constructed in a modular way that allows Insulator easy modification of component elements. Versions are available that allow expression of up to four open reading frames in addition to the selectable marker. Our stable vectors are built from several sets of mammalian functional elements: ⬤ Metabolic selectable markers ⬤ RNA processing elements Glutamine synthase (GS), dihydrofolate Introns, post-transcriptional response reductase (DHFR) elements ⬤ Drug-resistance markers ⬤ Insulators puromycin, blasticidin, hygromycin, Flanking the construct, and isolating neomycin, zeocin transcriptional units from each other ⬤ Promoters EF1a, CMV (murine and human), hybrids The total number of possible combinations of these is very large, and we do not have all of these built. However construction is modular, so it is easy for us to create custom combinations if we don’t have the combination you want. 6 www.atum.bio MAMMALIAN EXPRESSION One Vector, Two (or more) Open Reading Frames Co-transfection of separate vectors containing chain to obtain high titers. If genes encoding the genes for heavy and light chains is a common two chains are incorporated into the production method for producing antibody from transiently host genome independently, the number of transfected cells. This approach is less desirable gene copies integrated, and integration position for stable cell line generation. The production of effects, will influence the relative expression of the properly assembled antibody requires
Load more

Recommended publications
  • Plant Molecular Farming: a Viable Platform for Recombinant Biopharmaceutical Production
    plants Review Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production Balamurugan Shanmugaraj 1,2, Christine Joy I. Bulaon 2 and Waranyoo Phoolcharoen 1,2,* 1 Research Unit for Plant-Produced Pharmaceuticals, Chulalongkorn University, Bangkok 10330, Thailand; [email protected] 2 Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences Chulalongkorn University, Bangkok 10330, Thailand; [email protected] * Correspondence: [email protected]; Tel.: +66-2-218-8359; Fax: +66-2-218-8357 Received: 1 May 2020; Accepted: 30 June 2020; Published: 4 July 2020 Abstract: The demand for recombinant proteins in terms of quality, quantity, and diversity is increasing steadily, which is attracting global attention for the development of new recombinant protein production technologies and the engineering of conventional established expression systems based on bacteria or mammalian cell cultures. Since the advancements of plant genetic engineering in the 1980s, plants have been used for the production of economically valuable, biologically active non-native proteins or biopharmaceuticals, the concept termed as plant molecular farming (PMF). PMF is considered as a cost-effective technology that has grown and advanced tremendously over the past two decades. The development and improvement of the transient expression system has significantly reduced the protein production timeline and greatly improved the protein yield in plants. The major factors that drive the plant-based platform towards potential competitors for the conventional expression system are cost-effectiveness, scalability, flexibility, versatility, and robustness of the system. Many biopharmaceuticals including recombinant vaccine antigens, monoclonal antibodies, and other commercially viable proteins are produced in plants, some of which are in the pre-clinical and clinical pipeline.
    [Show full text]
  • Therapeutic Recombinant Protein Production in Plants: Challenges and Opportunities
    Received: 25 April 2019 | Revised: 23 July 2019 | Accepted: 20 August 2019 DOI: 10.1002/ppp3.10073 REVIEW Therapeutic recombinant protein production in plants: Challenges and opportunities Matthew J. B. Burnett1 | Angela C. Burnett2 1Yale Jackson Institute for Global Affairs, New Haven, CT, USA Societal Impact Statement 2Brookhaven National Laboratory, Upton, Therapeutic protein production in plants is an area of great potential for increasing NY, USA and improving the production of proteins for the treatment or prevention of disease Correspondence in humans and other animals. There are a number of key benefits of this technique Angela C. Burnett, Brookhaven National for scientists and society, as well as regulatory challenges that need to be overcome Laboratory, Upton, NY, USA. Email: [email protected] by policymakers. Increased public understanding of the costs and benefits of thera‐ peutic protein production in plants will be instrumental in increasing the acceptance, Funding information Biotechnology and Biological Sciences and thus the medical and veterinary impact, of this approach. Research Council; Margaret Claire Ryan Summary Fellowship Fund at the Yale Jackson Institute for Global Affairs; U.S. Department Therapeutic recombinant proteins are a powerful tool for combating many diseases of Energy, Grant/Award Number: DE‐ which have previously been hard to treat. The most utilized expression systems are SC0012704 Chinese Hamster Ovary cells and Escherichia coli, but all available expression sys‐ tems have strengths and weaknesses regarding development time, cost, protein size, yield, growth conditions, posttranslational modifications and regulatory approval. The plant industry is well established and growing and harvesting crops is easy and affordable using current infrastructure.
    [Show full text]
  • Gene Therapy Glossary of Terms
    GENE THERAPY GLOSSARY OF TERMS A • Phase 3: A phase of research to describe clinical trials • Allele: one of two or more alternative forms of a gene that that gather more information about a drug’s safety and arise by mutation and are found at the same place on a effectiveness by studying different populations and chromosome. different dosages and by using the drug in combination • Adeno-Associated Virus: A single stranded DNA virus that has with other drugs. These studies typically involve more not been found to cause disease in humans. This type of virus participants.7 is the most frequently used in gene therapy.1 • Phase 4: A phase of research to describe clinical trials • Adenovirus: A member of a family of viruses that can cause occurring after FDA has approved a drug for marketing. infections in the respiratory tract, eye, and gastrointestinal They include post market requirement and commitment tract. studies that are required of or agreed to by the study • Adeno-Associated Virus Vector: Adeno viruses used as sponsor. These trials gather additional information about a vehicles for genes, whose core genetic material has been drug’s safety, efficacy, or optimal use.8 removed and replaced by the FVIII- or FIX-gene • Codon: a sequence of three nucleotides in DNA or RNA • Amino Acids: building block of a protein that gives instructions to add a specific amino acid to an • Antibody: a protein produced by immune cells called B-cells elongating protein in response to a foreign molecule; acts by binding to the • CRISPR: a family of DNA sequences that can be cleaved by molecule and often making it inactive or targeting it for specific enzymes, and therefore serve as a guide to cut out destruction and insert genes.
    [Show full text]
  • Eukaryotic Expression
    Molecular Biology Problem Solver: A Laboratory Guide. Edited by Alan S. Gerstein Copyright © 2001 by Wiley-Liss, Inc. ISBNs: 0-471-37972-7 (Paper); 0-471-22390-5 (Electronic) 16 Eukaryotic Expression John J. Trill, Robert Kirkpatrick, Allan R. Shatzman, and Alice Marcy Section A: A Practical Guide to Eukaryotic Expression . 492 Planning the Eukaryotic Expression Project . 493 What Is the Intended Use of the Protein and What Quantity Is Required? . 493 What Do You Know about the Gene and the Gene Product? . 496 Can You Obtain the cDNA? . 497 Expression Vector Design and Subcloning . 498 Selecting an Appropriate Expression Host . 501 Selecting an Appropriate Expression Vector . 506 Implementing the Eukaryotic Expression Experiment . 511 Media Requirements, Gene Transfer, and Selection . 511 Scale-up and Harvest . 514 Gene Expression Analysis . 515 Troubleshooting . 517 Confirm Sequence and Vector Design . 517 Investigate Alternate Hosts . 519 A Case Study of an Expressed Protein from cDNA to Harvest.......................................... 519 Summary . 521 Section B: Working with Baculovirus . 521 Planning the Baculovirus Experiment . 521 491 Is an Insect Cell System Suitable for the Expression of Your Protein? . 521 Should You Express Your Protein in an Insect Cell Line or Recombinant Baculovirus? . 522 Procedures for Preparing Recombinant Baculovirus . 524 Criteria for Selecting a Transfer Vector . 524 Which Insect Cell Host Is Most Appropriate for Your Situation? . 525 Implementing the Baculovirus Experiment . 527 What’s the Best Approach to Scale-Up? . 527 What Special Considerations Are There for Expressing Secreted Proteins? . 527 What Special Considerations Are There for Expressing Glycosylated Proteins? . 528 What Are the Options for Expressing More Than One Protein?....................................
    [Show full text]
  • Lecture 3 Types, Biology and Salient Features of Vectors in Recombinant
    NPTEL – Bio Technology – Genetic Engineering & Applications MODULE 1- LECTURE 3 TYPES, BIOLOGY AND SALIENT FEATURES OF VECTORS IN RECOMBINANT DNA TECHNOLOGY – PLASMID 1-3.1 Introduction: DNA molecule used for carrying an exogenous DNA into a host organism and facilitates stable integration and replication inside the host system is termed as Vector. Molecular cloning involves series of sequential steps which includes restriction digestion of DNA fragments both target DNA and vector, ligation of the target DNA with the vector and introduction into a host organism for multiplication. Then the fragments resulted after digestion with restriction enzymes are ligated to other DNA molecules that serve as vectors. In general, vectors should have following characteristics: • Capable of replicating inside the host. • Have compatible restriction site for insertion of DNA molecule (insert). • Capable of autonomous replication inside the host (ori site). • Smaller in size and able to incorporate larger insert size. • Have a selectable marker for screening of recombinant organism. 1-3.2 Plasmids: • Plasmids are naturally occurring extra chromosomal double-stranded circular DNA molecules which can autonomously replicate inside bacterial cells. Plasmids range in size from about 1.0 kb to over 250 kb. • Plasmids encode only few proteins required for their own replication (replication proteins) and these proteins encoding genes are located very close to the ori. All the other proteins required for replication, e.g. DNA polymerases, DNA ligase, helicase, etc., are provided by the host cell.Thus, only a small region surrounding Joint initiative of IITs and IISc – Funded by MHRD Page 28 of 84 NPTEL – Bio Technology – Genetic Engineering & Applications the ori site is required for replication.
    [Show full text]
  • Molecular Biology and Applied Genetics
    MOLECULAR BIOLOGY AND APPLIED GENETICS FOR Medical Laboratory Technology Students Upgraded Lecture Note Series Mohammed Awole Adem Jimma University MOLECULAR BIOLOGY AND APPLIED GENETICS For Medical Laboratory Technician Students Lecture Note Series Mohammed Awole Adem Upgraded - 2006 In collaboration with The Carter Center (EPHTI) and The Federal Democratic Republic of Ethiopia Ministry of Education and Ministry of Health Jimma University PREFACE The problem faced today in the learning and teaching of Applied Genetics and Molecular Biology for laboratory technologists in universities, colleges andhealth institutions primarily from the unavailability of textbooks that focus on the needs of Ethiopian students. This lecture note has been prepared with the primary aim of alleviating the problems encountered in the teaching of Medical Applied Genetics and Molecular Biology course and in minimizing discrepancies prevailing among the different teaching and training health institutions. It can also be used in teaching any introductory course on medical Applied Genetics and Molecular Biology and as a reference material. This lecture note is specifically designed for medical laboratory technologists, and includes only those areas of molecular cell biology and Applied Genetics relevant to degree-level understanding of modern laboratory technology. Since genetics is prerequisite course to molecular biology, the lecture note starts with Genetics i followed by Molecular Biology. It provides students with molecular background to enable them to understand and critically analyze recent advances in laboratory sciences. Finally, it contains a glossary, which summarizes important terminologies used in the text. Each chapter begins by specific learning objectives and at the end of each chapter review questions are also included.
    [Show full text]
  • Regulation of Transgene Expression in Genetic Immunization
    Brazilian Journal of Medical and Biological Research (1999) 32: 155-162 Regulation of transgene expression 155 ISSN 0100-879X Regulation of transgene expression in genetic immunization J.S. Harms1, 1Department of Animal Health and Biomedical Sciences, University of Wisconsin, S.C. Oliveira2 Madison, WI, USA and G.A. Splitter1 2Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil Abstract Correspondence The use of mammalian gene expression vectors has become increas- Key words J.S. Harms ingly important for genetic immunization and gene therapy as well as · DNA vaccine AHABS basic research. Essential for the success of these vectors in genetic · Gene therapy 1655 Linden Drive · immunization is the proper choice of a promoter linked to the antigen Regulation Madison, WI 53706 · Transcription of interest. Many genetic immunization vectors use promoter elements USA · Transgene Fax: +1-608-262-7420 from pathogenic viruses including SV40 and CMV. Lymphokines E-mail: [email protected] produced by the immune response to proteins expressed by these vectors could inhibit further transcription initiation by viral promot- Research supported by the Robert ers. Our objective was to determine the effect of IFN-g on transgene Draper Technology Innovation Fund expression driven by viral SV40 or CMV promoter/enhancer and the (No. 135-0546) of the University mammalian promoter/enhancer for the major histocompatibility com- of Wisconsin, Madison. plex class I (MHC I) gene. We transfected the luciferase gene driven Presented at the International by these three promoters into 14 cell lines of many tissues and several Symposium “The Third Revolution species.
    [Show full text]
  • RNA Viruses As Tools in Gene Therapy and Vaccine Development
    G C A T T A C G G C A T genes Review RNA Viruses as Tools in Gene Therapy and Vaccine Development Kenneth Lundstrom PanTherapeutics, Rte de Lavaux 49, CH1095 Lutry, Switzerland; [email protected]; Tel.: +41-79-776-6351 Received: 31 January 2019; Accepted: 21 February 2019; Published: 1 March 2019 Abstract: RNA viruses have been subjected to substantial engineering efforts to support gene therapy applications and vaccine development. Typically, retroviruses, lentiviruses, alphaviruses, flaviviruses rhabdoviruses, measles viruses, Newcastle disease viruses, and picornaviruses have been employed as expression vectors for treatment of various diseases including different types of cancers, hemophilia, and infectious diseases. Moreover, vaccination with viral vectors has evaluated immunogenicity against infectious agents and protection against challenges with pathogenic organisms. Several preclinical studies in animal models have confirmed both immune responses and protection against lethal challenges. Similarly, administration of RNA viral vectors in animals implanted with tumor xenografts resulted in tumor regression and prolonged survival, and in some cases complete tumor clearance. Based on preclinical results, clinical trials have been conducted to establish the safety of RNA virus delivery. Moreover, stem cell-based lentiviral therapy provided life-long production of factor VIII potentially generating a cure for hemophilia A. Several clinical trials on cancer patients have generated anti-tumor activity, prolonged survival, and
    [Show full text]
  • Clone the Unclonable – Vectors and Cells to Capture and Express Problematic Dnas
    Clone the Unclonable – Vectors and Cells to Capture and Express Problematic DNAs Ron Godiska, Ph.D. May, 2016 Agenda Improve Cloning and Expression of Problematic DNA • What makes DNA difficult to clone or express? • Circular vectors for difficult DNAs • Linear vectors for “impossible” DNAs • Enzyme-free cloning and compatible protein expression vectors • E. coli strains for toxic recombinant proteins or unstable DNA What is Unclonable DNA? Characteristics of Difficult DNA • Toxic coding sequences • Promoters • A-T Rich DNA • Large fragments (>10 kb) • Trace amounts Which types of difficult DNA have you worked with in the lab? Common Vector Traits Cause Cloning Problems Vector driven transcription into the insert – Deleterious expression – Destabilize 2o structure Insert driven transcription out into the vector – False negatives (blue or lethal) – Transcriptional interference pUC19 – Replication interference High copy number – Increased effect of the above issues – Active origin – Many copies/cell Supercoiling – Deletion of secondary structures CloneSmart® Technology “Silencing” DNA Inserts to Improve Cloning • No Transcriptional Interference – Stably maintain “unclonable” DNA • No blue/white screening – No false positives/negatives • Minimal vector size • Variable copy number • Variety of drug selection markers • Very low empty-vector background U.S. Patent 6,709,861 pSMART Vectors Clone Toxic Inserts and Promoters Test DNA Fragments: • RNase coding sequence (350 bp; no promoter) • Phage Lambda PR Promoter (400 bp) pSMART Vectors cDNA Clones are More Stable Deletion Rates: <1% in pSMART HC Kan vs. 32% in pUC % Deleted Clones Insert Size (kb) • Teleost fish cDNA library • Clones were grown in liquid medium, diluted, and regrown • Each final culture was diluted, plated, and grown up into individual colonies • Plasmid DNA was isolated from colonies for each clone and analyzed - Oleksiak M.F., Crawford D.L., 2001.
    [Show full text]
  • Recent Advances in Genome Editing Tools in Medical Mycology Research
    Journal of Fungi Review Recent Advances in Genome Editing Tools in Medical Mycology Research Sanaz Nargesi 1 , Saeed Kaboli 2,3,* , Jose Thekkiniath 4,*, Somayeh Heidari 5 , Fatemeh Keramati 6, Seyedmojtaba Seyedmousavi 5,7 and Mohammad Taghi Hedayati 1,5,* 1 Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari 481751665, Iran; [email protected] 2 Department of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan 4513956111, Iran 3 Cancer Gene Therapy Research Center, Zanjan University of Medical Sciences, Zanjan 4513956111, Iran 4 Fuller Laboratories, 1312 East Valencia Drive, Fullerton, CA 92831, USA 5 Invasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari 481751665, Iran; [email protected] (S.H.); [email protected] (S.S.) 6 Department of Pathobiology, Faculty of Veterinary Medicine, Urmia University, Urmia 5756151818, Iran; [email protected] 7 Clinical Center, Microbiology Service, Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD 20892, USA * Correspondence: [email protected] (S.K.); [email protected] (J.T.); [email protected] (M.T.H.) Abstract: Manipulating fungal genomes is an important tool to understand the function of tar- get genes, pathobiology of fungal infections, virulence potential, and pathogenicity of medically important fungi, and to develop novel diagnostics and therapeutic targets. Here, we provide an overview of recent advances in genetic manipulation techniques used in the field of medical mycol- Citation: Nargesi, S.; Kaboli, S.; ogy. Fungi use several strategies to cope with stress and adapt themselves against environmental Thekkiniath, J.; Heidari, S.; Keramati, effectors. For instance, mutations in the 14 alpha-demethylase gene may result in azole resistance in F.; Seyedmousavi, S.; Hedayati, M.T.
    [Show full text]
  • An Improved Syringe Agroinfiltration Protocol to Enhance Transformation Efficiency by Combinative Use of 5-Azacytidine, Ascorbat
    plants Article An Improved Syringe Agroinfiltration Protocol to Enhance Transformation Efficiency by Combinative Use of 5-Azacytidine, Ascorbate Acid and Tween-20 Huimin Zhao 1, Zilong Tan 2, Xuejing Wen 2 and Yucheng Wang 1,2,* 1 State Key Laboratory of Tree Genetics and Breeding, Northeast Forestry University, Harbin 150040, China; [email protected] 2 Key Laboratory of Biogeography and Bioresource in Arid Land, Xinjiang Institute of Ecology and Geography, Chinese Academy of Sciences, Urumqi 830011, China; [email protected] (Z.T.); [email protected] (X.W.) * Correspondence: [email protected]; Tel.: +86-451-82190607 Academic Editor: Milan S. Stankovic Received: 1 January 2017; Accepted: 9 February 2017; Published: 14 February 2017 Abstract: Syringe infiltration is an important transient transformation method that is widely used in many molecular studies. Owing to the wide use of syringe agroinfiltration, it is important and necessary to improve its transformation efficiency. Here, we studied the factors influencing the transformation efficiency of syringe agroinfiltration. The pCAMBIA1301 was transformed into Nicotiana benthamiana leaves for investigation. The effects of 5-azacytidine (AzaC), Ascorbate acid (ASC) and Tween-20 on transformation were studied. The β-glucuronidase (GUS) expression and GUS activity were respectively measured to determine the transformation efficiency. AzaC, ASC and Tween-20 all significantly affected the transformation efficiency of agroinfiltration, and the optimal concentrations of AzaC, ASC and Tween-20 for the transgene expression were identified. Our results showed that 20 µM AzaC, 0.56 mM ASC and 0.03% (v/v) Tween-20 is the optimal concentration that could significantly improve the transformation efficiency of agroinfiltration.
    [Show full text]
  • Highly Efficient Protoplast Isolation and Transient Expression System
    International Journal of Molecular Sciences Article Highly Efficient Protoplast Isolation and Transient Expression System for Functional Characterization of Flowering Related Genes in Cymbidium Orchids Rui Ren 1 , Jie Gao 1, Chuqiao Lu 1, Yonglu Wei 1, Jianpeng Jin 1, Sek-Man Wong 2,3,4, Genfa Zhu 1,* and Fengxi Yang 1,* 1 Guangdong Key Laboratory of Ornamental Plant Germplasm Innovation and Utilization, Environmental Horticulture Research Institute, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China; [email protected] (R.R.); [email protected] (J.G.); [email protected] (C.L.); [email protected] (Y.W.); [email protected] (J.J.) 2 Department of Biological Sciences, National University of Singapore (NUS), 14 Science Drive 4, Singapore 117543, Singapore; [email protected] 3 National University of Singapore Suzhou Research Institute (NUSRI), Suzhou Industrial Park, Suzhou 215000, China 4 Temasek Life Sciences Laboratory, National University of Singapore, 1 Research Link, Singapore 117604, Singapore * Correspondence: [email protected] (G.Z.); [email protected] (F.Y.) Received: 28 February 2020; Accepted: 24 March 2020; Published: 25 March 2020 Abstract: Protoplast systems have been proven powerful tools in modern plant biology. However, successful preparation of abundant viable protoplasts remains a challenge for Cymbidium orchids. Herein, we established an efficient protoplast isolation protocol from orchid petals through optimization of enzymatic conditions. It requires optimal D-mannitol concentration (0.5 M), enzyme concentration (1.2 % (w/v) cellulose and 0.6 % (w/v) macerozyme) and digestion time (6 h). With this protocol, the highest yield (3.50 107/g fresh weight of orchid tissue) and viability (94.21%) of × protoplasts were obtained from flower petals of Cymbidium.
    [Show full text]